Genetic disruption of angiotensin II type 1a receptor improves long-term survival of mice with chronic severe aortic regurgitation

Circulation Journal

Volumn 71, Issue 8, 2007, Pages 1310-1316

  Nakanishi, Michio ^a   Harada, Masaki ^a   Kishimoto, Ichiro ^b   Kuwahara, Koichiro ^a   Kawakami, Rika ^a   Nakagawa, Yasuaki ^a   Yasuno, Shinji ^a   Usami, Satoru ^a   Kinoshita, Hideyuki ^a   Adachi, Yuichiro ^a   Fukamizu, Akiyoshi ^c   Saito, Yoshihiko ^d   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin; Fibrosis; Heart failure; Hypertrophy; Valvular disease

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE; AORTA VALVE REGURGITATION; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; GENE DISRUPTION; GENE EXPRESSION; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; KNOCKOUT MOUSE; MALE; MEASUREMENT; MOUSE; NONHUMAN; RECEPTOR GENE; STRAIN DIFFERENCE; SURVIVAL TIME; VASCULAR DISEASE; WILD TYPE;

ANIMALS; AORTIC VALVE INSUFFICIENCY; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HEART FAILURE, CONGESTIVE; MICE; MICE, KNOCKOUT; NATRIURETIC PEPTIDE, BRAIN; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34547598307     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1310     Document Type: Article

References (32)

1. Bonow RO, Dodd JT, Maron BJ, O'Gara PT, White GG, McIntosh CL, et al. Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation 1988; 78: 1108-1120.
2. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice: A long-term follow up study. Circulation 1999; 99: 1851-1857.
3. Borer JS, Bonow RO. Contemporary approach to aortic and mitral regurgitation. Circulation 2003; 108: 2432-2438.
4. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991; 84: 1625-1635.
5. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 2002; 106: 2687-2693.
6. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, et al. Long-term vasodilator therapy of chronic aortic insufficiency: A randomized double-blinded, placebo-controlled clinical trial. Circulation 1988; 78: 92-103.
7. Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S. Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation. J Am Coll Cardiol 1990; 16: 424-429.
8. Schon HR, Dorn R, Barthel P, Schomig A. Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis 1994; 3: 500-509.
9. Sondergaard L, Aldershvile J, Hildebrandt P, Kelbaek H, Stahlberg F, Thomsen C. Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. Am Heart J 2000; 139: 667-674.
10. Nauman D, Greenberg B, Massie B, Bristow JD, Cheitlin M. Effects of stopping long-term vasodilator therapy in patients with chronic aortic insufficiency. Chest 1992; 102: 720-724.
11. Perry GJ, Wei CC, Hankes GH, Dillon SR, Rynders P, Mukherjee R, et al. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 2002; 39: 1374-1379.
12. Supino PG, Borer JS, Herrold EM, Hochreiter CA, Preibisz J, Schuleri K, et al. Prognostic impact of systolic hypertension on asymptomatic patients with chronic severe aortic regurgitation and initially normal left ventricular performance at rest. Am J Cardiol 2005; 96: 964-970.
13. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994; 331: 689-694.
14. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353: 1342-1349.
15. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685-691.
17. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
18. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
19. Plante E, Gaudreau M, Lachance D, Drolet MC, Roussel E, Gauthier C, et al. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Can J Physiol Pharmacol 2004; 82: 191-199.
20. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995; 270: 18719-18722.
21. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100: 2093-2099.
22. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, et al. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 2002; 106: 1722-1728.
23. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Kim S, Takeuchi K, et al. Transmitral inflow pattern assessed by Doppler echocardiography in angiotensin II type 1A receptor knockout mice with myocardial infarction. Circ J 2002; 66: 192-196.
24. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, et al. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 2004; 145: 951-958.
25. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
26. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995; 91: 161-170.
27. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
28. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
29. Schraeger JA, Canby CA, Rongish BJ, Kawai M, Tomanek RJ. Normal left ventricular diastolic compliance after regression of hypertrophy. J Cardiovasc Pharmacol 1994; 23: 349-357.
30. Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: Enalapril versus hydralazine therapy. J Am Coll Cardiol 1994; 24: 1046-1053.
31. Banaszewski M, Rydlewska-Sadowska W, Rubkiewicz S. Captopril or nifedipine?: Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. J Heart Valve Dis 1998; 7: 488-499.
32. Yamakawa H, Imamura T, Matsuo T, Onitsuka H, Tsumori Y, Kato J, et al. Diastolic wall stress and ANG II in cardiac hypertrophy and gene expression induced by volume overload. Am J Physiol Heart Circ Physiol 2000; 279: H2939-H2946.